Home / Pharmaceuticals / Global Anti-Hypertensive Drugs Market By Type (Diuretics, ACE inhibitors, ARBs, Calcium Channel Blockers, Beta - Adrenergic blocker, Alpha - Adrenergic blocker, Central Sympatholyics, Renin inhibitors, Vasodilators): Market Growth, Future Prospects And Competitive Analysis, 2016 - 2023

Global Anti-Hypertensive Drugs Market By Type (Diuretics, ACE inhibitors, ARBs, Calcium Channel Blockers, Beta - Adrenergic blocker, Alpha - Adrenergic blocker, Central Sympatholyics, Renin inhibitors, Vasodilators): Market Growth, Future Prospects And Competitive Analysis, 2016 - 2023

Published: Dec 2016 | Report Code: 58287-12-16

Hypertension is most commonly observed chronic disease, which causes elevation in systolic and diastolic blood pressure, which in long term is high risk factor for coronary artery disease, heart failure, stroke etc.. The anti-hypertensive drugs are used to control the blood pressure. The antihypertensive drugs market major drivers is the prevalence of the chronic disease along with growing population and altering lifestyle, with increase in awareness of treatment, new drug approval and healthcare expenditure.

The report titled “Global Anti-Hypertensive Drugs Market - Growth, Share, Opportunities and Competitive Analysis, 2016–2023” offers strategic insights into the overall anti-hypertensive drugs market along with the market size and estimates for the duration 2016 to 2023. The said research study covers in-depth analysis of multiple market segments based on type of drug class and different geographical region. The Drug class type segment studied for analyzing the overall anti-hypertensive drugs market is majorly segmented into Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in anti-hypertensive drugs market, pipeline analysis, attractive investment proposition market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Geographically, the global anti-hypertensive drugs market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2013-2023. Market growth rates for the forecast period 2016-2023 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global anti-hypertensive drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global anti-hypertensive drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global anti-hypertensive drugs market. In-depth competitive environment analysis and historical years (2013 & 2014) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global anti-hypertensive drug market, offering market size and estimates for the period from 2016 to 2023, keeping in mind the above-mentioned factors.


Anti-Hypertensive Drugs Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Anti-Hypertensive Drugs Market Portraiture
2.2 Global Anti-Hypertensive Drugs Market Share, by Drug type, 2015 (US$ Mn)
2.3 Global Anti-Hypertensive Drugs Market, by Geography, 2015 (Value %)

Chapter 3 Global Anti-Hypertensive Drugs Market Analysis
3.1 Hypertension
3.1.1 Epidemiology
3.1.2 Treatment
3.2 Prescription Analysis
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Prevalence of chronic diseases
3.3.1.2 Rise in R&D and new drug approval
3.3.2 Challenges
3.3.2.1 Adverse effects of anti-hypertensive
3.3.3 Opportunities
3.3.3.1 Use of combination therapy and to address the unmet needs
3.4 Attractive Investment Proposition
3.5 Pipeline Analysis
3.6 Market Positioning of Key Players in Anti-Hypertensive Drugs

Chapter 4 Global Anti-Hypertensive Drugs Market Analysis, by Drug Type, 2013-2023 (US$ Mn)
4.1 Introduction
4.2 Diuretics
4.3 ACE inhibitors
4.4 ARBs
4.5 Calcium Channel Blockers
4.6 Beta - Adrenergic blocker
4.7 Alpha - Adrenergic blocker
4.8 Central Sympatholyics
4.9 Renin inhibitors
4.10 Vasodilators

Chapter 5 Global Anti-Hypertensive Drugs Market, by Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of APAC)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)

Chapter 6 Company Profiles
6.1 Novartis AG
6.2 Astra zeneca
6.3 Daiichyi Sankyo Co. Ltd
6.4 Takeda Pharmaceutical
6.5 Sanofi
6.6 Merck & Co
6.7 Boehinger Ingelheim
6.8 Pfizer
6.9 Bayer AG
6.10 Lupin Limited
6.11 Johnson & Johnson
6.12 Actelion Ltd
6.13 Ranbaxy Laboratories Limited
6.14 Other Notable Players

Note:

  • Profiles of specific players, if required, shall be added to the report upon request

List of Tables :

TABLE 1 Global Anti-Hypertensive Drugs Market, By Drug Type 2013 - 2023 (US$ Mn)
TABLE 2 Global Anti-Hypertensive Drugs Market, by Geography, 2013 – 2023 (US$ Mn)
TABLE 3 North America Anti-Hypertensive Drugs Market, by Country, 2013 – 2023 (US$ Mn)
TABLE 4 Europe Anti-Hypertensive Drugs Market, by Country, 2013 – 2023 (US$ Mn)
TABLE 5 Asia-Pacific Anti-Hypertensive Drugs Market, by Country, 2013 – 2023 (US$ Mn)
TABLE 6 Latin America Anti-Hypertensive Drugs Market, by Country, 2013 – 2023 (US$ Mn)
TABLE 7 Middle East and Africa Anti-Hypertensive Drugs Market, by Country, 2013 – 2023 (US$ Mn)
TABLE 8 A Novartis AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 9 Astra zeneca: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 10 Daiichyi Sankyo Co. Ltd: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 11 Takeda Pharmaceutical: Company Snapshot (Business Description; Financial Performance; Product Position Portfolio; News Coverage)
TABLE 12 C Sanofi: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 13 Merck & Co: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 C Boehinger Ingelheim: : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Pfizer: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 16 Bayer AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 17 Lupin Limited: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Johnson & Johnson: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Actelion Ltd: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 Ranbaxy Laboratories Limited: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)

List of Figures :

FIG. 1 Global Anti-Hypertensive Drugs Market: Research Methodology
FIG. 2 Global Anti-Hypertensive Drugs Market Share, by Products type, 2015 (US$ Mn)
FIG. 3 Global Anti-Hypertensive Drugs Market, by Geography, 2015 (Value %)
FIG. 4 Attractive Investment Proposition: Global Anti-Hypertensive Drugs Market, by Geography
FIG. 5 Market Positioning of Key Players in Anti-Hypertensive Drugs
FIG. 6 Global Diuretics Market in Anti-Hypertensive Drugs, 2013 – 2023 (US$ Mn )
FIG. 7 Global ACE inhibitors Market in Anti-Hypertensive Drugs, 2013 – 2023 (US$ Mn )
FIG. 8 Global ARBs Market in Anti-Hypertensive Drugs, 2013 – 2023 (US$ Mn )
FIG. 9 Global Calcium Channel Blockers Market in Anti-Hypertensive Drugs, 2013 – 2023 (US$ Mn)
FIG. 10 Global Beta - Adrenergic blocker Market in Anti-Hypertensive Drugs, 2013 – 2023 (US$ Mn)
FIG. 11 Global Alpha - Adrenergic blocker Monitors Market in Anti-Hypertensive Drugs, 2013 – 2023 (US$ Mn)
FIG. 12 Global Central Sympatholyics Market in Anti-Hypertensive Drugs, 2013 – 2023 (US$ Mn)
FIG. 13 Global Renin inhibitors Market in Anti-Hypertensive Drugs, 2013 – 2023 (US$ Mn)
FIG. 14 Global Vasodilators Market in Anti-Hypertensive Drugs, 2013 – 2023 (US$ Mn)

Based on the type of drug class, the global Anti-Hypertensive Drugs market is segmented as follows:

  • Diuretics
  • ACE inhibitors
  • ARBs
  • Calcium Channel Blockers
  • Beta - Adrenergic blocker
  • Alpha - Adrenergic blocker
  • Central Sympatholyics
  • Renin inhibitors
  • Vasodilators

The global Anti-Hypertensive Drugs market is segmented by drug class into different categories such as Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators. The ACE inhibitors controls the blood pressure by the by widening the blood vessel, which improve the blood flood of the heart. ACE inhibitor dominates the market share of the antihypertensive drugs market in value due to its mechanism of action, preference in geriatric population and cost. The next followed is beta blockers in antihypertensive drugs market which preferred by physician to reduce the blood pressure and risk of complication which is generally associated with chronic hypertension is less, plus with minimal side effects. Diuretic is next most commonly used anti-hypertensive drug in the market, as they are widely available and less expensive compared to others. The diuretics help in maintain the blood pressure by getting rid of the sodium and water. Diuretic is conventionally used first line of treatment, though the trend is changing with new drug entrants  approval and different mechanism of action which is further preferred by physician depending upon the suitability of the patient medical history; due to which ACE, Beta blocker, CCB, ARB etc. are used now-days and exist in market according to patient needs.

For the purpose of this study, the Global Anti-Hypertensive Drugs Market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Anti-Hypertensive Drugs Market

The global anti-hypertensive drugs market is bifurcated into four regions: North America, Europe, Asia-Pacific, Latin America and Middle East. The global Anti-Hypertensive Drug market is dominated by the North America region occupying the major market. The major contributor in this region is US due to factors such as the prevalence of hypertension, rise in geriatric population, upcoming new drug in pipeline and use of combination therapy. Europe is next followed up market with major contributor being UK, Germany, France, Italy and Spain. According to research studies, with rise in population of Europe, there is considerable increase in number of people suffering from hypertension, therefore to address the unmet need for appropriate health care planning and expenditure are the major driving factors for the European market. The Asia-pacific is the lucrative market, with major contributors being Japan, India and China. Asia-Pacific carries almost half of the world cardiovascular burden, in which upto 66% of subtype of CVD contribute to hypertension due to increase in urbanization and adoption of unhealthy lifestyle and food. Thus developed countries dominates the market of hypertensive, emerging economies with growing population and increasing government spending on health care is lucrative market.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients